We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00131118
First Posted: August 17, 2005
Last Update Posted: June 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
August 15, 2005
August 17, 2005
June 1, 2017
July 2004
May 2007   (Final data collection date for primary outcome measure)
Long-term safety of two different zoledronic acid doses over an additional 12 months in patients who have completed one year treatment in CZOL446H2202
Not Provided
Complete list of historical versions of study NCT00131118 on ClinicalTrials.gov Archive Site
Measure percentage change of lumbar spine bone mineral density at month 18 and 24 compared to baseline in the core study.
Not Provided
Not Provided
Not Provided
 
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Osteogenesis Imperfecta
Drug: Zoledronic Acid
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
127
May 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have completed the core CZOL446H2202 study
  • Males or females between 1-17 years of age

Exclusion Criteria:

  • Deformity or abnormality which would prevent spine bone density from being done
  • Any surgical bone-lengthening procedure
  • Any kidney diseases or abnormalities
  • Low calcium or vitamin D levels in the blood

Other protocol-defined inclusion/exclusion criteria may apply.

Sexes Eligible for Study: All
1 Year to 17 Years   (Child)
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00131118
CZOL446H2202E1
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Not Provided
Novartis
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP